Clinical utility of denosumab for treatment of bone loss in men and women

Robert A Adler, Ranjodh S GillEndocrinology and Metabolism, McGuire Veterans Affairs Medical Center, Richmond, VA, USAAbstract: While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, such drugs h...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adler R, Gill RS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Osteoporosis Fracture Denosumab Bisphosphonates Dual energy x-ray absorptiometry Androgen deprivation therapy Osteonecrosis of the jaw Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/75b6a79ef62d4aab9660aac39a7c9067
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75b6a79ef62d4aab9660aac39a7c9067
record_format	dspace
spelling	oai:doaj.org-article:75b6a79ef62d4aab9660aac39a7c90672021-12-02T07:09:20ZClinical utility of denosumab for treatment of bone loss in men and women1178-1998https://doaj.org/article/75b6a79ef62d4aab9660aac39a7c90672011-05-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-of-denosumab-for-treatment-of-bone-loss-in-men-and-wo-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Robert A Adler, Ranjodh S GillEndocrinology and Metabolism, McGuire Veterans Affairs Medical Center, Richmond, VA, USAAbstract: While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, such drugs have side effects, remain in bone for extended periods, and lead to poor adherence to chronic treatment. Denosumab is a humanized monoclonal antibody and antiresorptive agent that works by decreasing the activity of the receptor activator of nuclear factor kappa B ligand. In major trials in postmenopausal women, denosumab increased bone mineral density by dual energy x-ray absorptiometry in the spine, hip, and distal third of the radius and decreased vertebral, nonvertebral, and hip fractures. Denosumab is administered by subcutaneous injection every six months, suggesting that adherence may be improved with such therapy. In addition, pharmacokinetic studies measuring bone turnover markers imply that the antiresorptive effect diminishes more quickly over time. Whether these properties will lead to fewer long-term side effects needs to be proven. Denosumab has also been studied in men with prostate cancer treated with androgen deprivation therapy. These men, at high risk for fracture, also have increases in spine, hip, and forearm dual energy x-ray absorptiometry, as well as fewer morphologic vertebral fractures on x-ray. Denosumab is approved for postmenopausal women with osteoporosis in the US and Europe and for men on androgen deprivation therapy in Europe.Keywords: osteoporosis, fracture, denosumab, bisphosphonates, dual energy x-ray absorptiometry, androgen deprivation therapy, osteonecrosis of the jawAdler RGill RSDove Medical PressarticleOsteoporosisFractureDenosumabBisphosphonatesDual energy x-ray absorptiometryAndrogen deprivation therapyOsteonecrosis of the jawGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 6, Pp 119-124 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Osteoporosis Fracture Denosumab Bisphosphonates Dual energy x-ray absorptiometry Androgen deprivation therapy Osteonecrosis of the jaw Geriatrics RC952-954.6
spellingShingle	Osteoporosis Fracture Denosumab Bisphosphonates Dual energy x-ray absorptiometry Androgen deprivation therapy Osteonecrosis of the jaw Geriatrics RC952-954.6 Adler R Gill RS Clinical utility of denosumab for treatment of bone loss in men and women
description	Robert A Adler, Ranjodh S GillEndocrinology and Metabolism, McGuire Veterans Affairs Medical Center, Richmond, VA, USAAbstract: While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, such drugs have side effects, remain in bone for extended periods, and lead to poor adherence to chronic treatment. Denosumab is a humanized monoclonal antibody and antiresorptive agent that works by decreasing the activity of the receptor activator of nuclear factor kappa B ligand. In major trials in postmenopausal women, denosumab increased bone mineral density by dual energy x-ray absorptiometry in the spine, hip, and distal third of the radius and decreased vertebral, nonvertebral, and hip fractures. Denosumab is administered by subcutaneous injection every six months, suggesting that adherence may be improved with such therapy. In addition, pharmacokinetic studies measuring bone turnover markers imply that the antiresorptive effect diminishes more quickly over time. Whether these properties will lead to fewer long-term side effects needs to be proven. Denosumab has also been studied in men with prostate cancer treated with androgen deprivation therapy. These men, at high risk for fracture, also have increases in spine, hip, and forearm dual energy x-ray absorptiometry, as well as fewer morphologic vertebral fractures on x-ray. Denosumab is approved for postmenopausal women with osteoporosis in the US and Europe and for men on androgen deprivation therapy in Europe.Keywords: osteoporosis, fracture, denosumab, bisphosphonates, dual energy x-ray absorptiometry, androgen deprivation therapy, osteonecrosis of the jaw
format	article
author	Adler R Gill RS
author_facet	Adler R Gill RS
author_sort	Adler R
title	Clinical utility of denosumab for treatment of bone loss in men and women
title_short	Clinical utility of denosumab for treatment of bone loss in men and women
title_full	Clinical utility of denosumab for treatment of bone loss in men and women
title_fullStr	Clinical utility of denosumab for treatment of bone loss in men and women
title_full_unstemmed	Clinical utility of denosumab for treatment of bone loss in men and women
title_sort	clinical utility of denosumab for treatment of bone loss in men and women
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/75b6a79ef62d4aab9660aac39a7c9067
work_keys_str_mv	AT adlerr clinicalutilityofdenosumabfortreatmentofbonelossinmenandwomen AT gillrs clinicalutilityofdenosumabfortreatmentofbonelossinmenandwomen
_version_	1718399577874235392

Clinical utility of denosumab for treatment of bone loss in men and women

Ejemplares similares